Publications by authors named "G Zamperlini-Netto"
Outcomes after Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Patients with Primary Immunodeficiency Diseases.
Biol Blood Marrow Transplant
October 2020
Allogeneic hematopoietic stem cell transplantation (HCT) can cure primary immunodeficiency diseases (PID). When a HLA-matched donor is not available, a haploidentical family donor may be considered. The use of T cell-replete haploidentical HCT with post-transplantation cyclophosphamide (haplo-PTCy) in children with PID has been reported in few case series.
View Article and Find Full Text PDFArticle Synopsis
- Venous thrombotic events (VTE) are increasingly recognized in hospitalized children, with significant occurrences among those with renal tumors, posing management challenges in cases of vascular invasion.
- A retrospective study from The Hospital for Sick Children analyzed 292 pediatric patients with renal tumors from 1990 to 2012, identifying the prevalence of extra renal vascular involvement and associated clinical outcomes.
- Results showed that 29 out of 292 patients had vascular disease, predominantly related to Wilms tumors, and treatment strategies varied from chemotherapy to surgical interventions based on the extent of vascular involvement.
Langerhans cell histiocytosis is a rare disease characterized by clonal proliferation of Langerhans-type cells, causing local or systemic effects. One of the most affected sites in children is the skull. We describe 2 cases of children presenting to the pediatric emergency department with symptoms isolated to the scalp and the point-of-care focused skull ultrasound findings, which assisted in the diagnosis of Langerhans cell histiocytosis in both cases.
View Article and Find Full Text PDFBackground: Objective was to determine whether prophylactic low level laser therapy (LLLT) reduces the risk of severe mucositis as compared to placebo or no therapy.
Methods: MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials were searched until February 2014 for randomized controlled trials (RCTs) comparing prophylactic LLLT with placebo or no therapy in patients with cancer or undergoing hematopoietic stem cell transplantation (HSCT). All analyses used random effects models.